Highlights

• Current manufacturing turnaround times for CAR-T products (2-3 weeks) for ALL are not a major limitation for pediatric leukemia patients.
• CAR-T treatments may be more acutely toxic than transplant immediately after infusion, but patients may have fewer medium- and long-term complications.
• Agents that target the cell cycle (CDK inhibitors, Aurora kinase inhibitors) will likely be plagued with toxicity concerns, but they are perhaps no more toxic than chemotherapy.